News

Jul 30 2020

U.S. FDA Grants Ethicon Breakthrough Device Designation for Monarch-enabled NeuWave Microwave Ablation Technology

Oct 23 2019

Data Presented at CHEST 2019 Demonstrates Efficacy of Monarch to Successfully Reach Nodules and Biopsy Tissue * NEW ORLEANS – October 23, 2019 – Auris Health, Inc. (“Auris Health”), part of Johnson & Johnson Medical Devices Companies, today announced results from a study demonstrating the safety and feasibility of the Monarch Platform, a first-of-its-kind robotic technology indicated for use in diagnostic and therapeutic bronchoscopic procedures. Data from the BENEFIT study was presented in a late-breaking session at the CHEST 2019 Conference in New Orleans by Alexander C. Chen, M.D., of St. Louis, Mo.

Aug 26 2019

REDWOOD CITY – August 22, 2019 – Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies, today announced that physicians have performed over 1,000 bronchoscopic procedures using the Monarch™ Platform. Auris gained FDA clearance for diagnostic and therapeutic bronchoscopic procedures on the Monarch Platform in the Spring of 2018.

May 21 2019

Researchers conclude the Monarch™ Platform overcomes some limitations of conventional bronchoscopic systems in diagnosing lung nodules

May 20 2019

Ongoing BENEFIT Study of Monarch Platform Indicates Safety, Feasibility and Successful Localization of Lung Nodules in 92% of Cases

Apr 19 2019

Flagship Product Wins Gold Edison and Red Dot Awards Interactive

Apr 01 2019

Auris will Enable Johnson & Johnson to Deliver on the Promise of Digital Surgery and Drive Better Outcomes for Patients

Feb 13 2019

Auris Health’s Robotic Platform Expands Johnson & Johnson’s Digital Surgery Portfolio

Nov 28 2018

Funds Will Be Used to Advance Commercialization and Development of Next-Generation Robotic Interventional Technology

Oct 15 2018

ACCESS Study Demonstrates Ability of Monarch to Successfully Reach Nodules and Biopsy Tissue